Alan Selby
Managing Director
London Office | alan.selby@torreya.com | +44 (0) 207 451 4553
Alan Selby, a Managing Director at Torreya, works on strategic transactions and financings in addition to overseeing Torreya’s junior staff in London.
Before joining Torreya’s team in 2011, he was an Investment Manager at LGV, a UK-based middle-market private equity fund, focusing on healthcare investments. Alan also served as an advisor to the healthcare team at Booz & Company and at Macquarie Group from 2006 to 2009 where he worked on deals in healthcare, infrastructure, and structured finance.
Prior to his career in Finance, Alan was a practicing doctor in teaching hospitals in London specializing in neurology, infectious diseases, endocrinology, and elderly care.
Alan holds both an M.Sc. in finance from INSEAD and an M.B.Ch.B. with Hons., University of Liverpool, UK.
Selected Transactions
|
| Investment by |
|
|
January 2022
|
|
| Sale to |
|
|
$260 million
August 2021
|
|
| Acquired by |
|
|
November 2019
|
|
| Sale of majority stake to |
|
|
February 2019
|
|
| Merger with |
|
|
$251 million
December 2016
|
|
| Acquired by |
|
|
Up to CHF105 million
+ 1/3 of future net proceeds from a PRV sale September 2022
|
|
| Investment by |
|
|
£18 million
August 2022
|
|
| Sale of non-core UK Specials manufacturing and Aseptic compounding business to |
|
|
June 2021
|
|
| Sale of two orphan drug programs to |
|
|
August 2019
|
|
| Licensing of ex European rights for LYS-SAF302 to |
|
|
Up to $125 Millionwith committed payments of $29m plus royalties
October 2018
|
|
| Sale of royalties to |
|
|
$17.5 million
December 2016
|
|
| License of milk allergy product to |
|
|
€100 million
May 2016
|
|
| License of preclinical derm antibody to |
|
|
Up to €105 million
May 2015
|
|
| Acquisition of |
|
|
Up to €50 million
May 2015
|
|
| License of naloxone opioid overdose reversal treatment to |
|
|
$55+ million
December 2014
|
|
| License of antimicrobial technology to |
|
|
December 2014
|
|
|
| Global offering advisory |
|
|
$133 million
October 2014
|
|
| Sale to |
|
|
$40+ million with
$10 million upfront January 2014
|
|
| License of chemotherapy benefit test for high risk breast cancer to |
|
|
$9 million + milestones and royalties
November 2013
|
|
|
| Financial advisor in private placement |
|
|
|
€29.9 million
November 2013
|
|
| Sale of vaccine company to |
|
|
$250 million with
$35 million upfront May 2013
|
|
| Sale of basket of royalties to |
|
|
$6 million upfront
April 2013
|
|
| Collaboration with |
|
|
December 2012
|